ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -10 مورد

Complications of nephrotic syndrome in children

Complications of nephrotic syndrome in children
Author:
Patrick Niaudet, MD
Section Editor:
Tej K Mattoo, MD, DCH, FRCP
Deputy Editor:
Jessica Kremen, MD
Literature review current through: Apr 2025. | This topic last updated: Mar 06, 2024.

INTRODUCTION — 

The nephrotic syndrome is caused by kidney diseases that increase the permeability across the glomerular filtration barrier. It is classically characterized by four features, but the first two are used diagnostically because the last two may not be seen in all patients:

Nephrotic-range proteinuria – Urinary protein excretion greater than 50 mg/kg per day

Hypoalbuminemia – Serum albumin concentration less than 3 g/dL (30 g/L)

Edema

Hyperlipidemia

Complications in children result from abnormalities directly related to the nephrotic syndrome and, secondarily, from therapy used for its treatment.

The five major complications directly related to the underlying nephrotic syndrome in children will be reviewed here:

Infection

Thromboembolism

Kidney function impairment

Anasarca

Hypovolemia

The clinical manifestations, diagnosis, etiology, and treatment, including complications due to therapy in children with nephrotic syndrome, are discussed separately. (See "Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children" and "Treatment of idiopathic nephrotic syndrome in children".)

INFECTION — 

Children with nephrotic syndrome are at increased risk of infection. The following factors may contribute to this problem:

Reduced serum concentrations of immunoglobulin G (IgG) [1]

Impaired ability to make specific antibodies [2]

Decreased levels of the alternative complement pathway factors B and D [3-5]

Immunosuppressive therapy

The frequency and types of infection were evaluated in an observational study from India of 60 children with nephrotic syndrome who were not receiving glucocorticoid therapy [6]. There were 57 episodes of infection, which included:

Upper respiratory infection – 16 episodes

Urinary tract infection – 13 episodes

Peritonitis – 9 episodes

Pneumonia – 8 episodes

Severe acute gastroenteritis – 6 episodes

Empyema – 3 episodes

Bacterial infection — Children with nephrotic syndrome are at increased risk of developing serious bacterial infection, especially with encapsulated bacteria. This may be due in part to the loss of opsonizing factors, which may specifically increase susceptibility to encapsulated bacterial infection [3,5]. In addition, ascites and pleural effusions provide a natural culture media for bacterial growth. Thus, as noted in the above study, pneumonia, empyema, and peritonitis are infections seen in children with nephrotic syndrome [6].

In a retrospective review, 24 episodes of peritonitis occurred in 351 children with nephrotic syndrome over a 10-year period from 1970 to 1980 [7]. Streptococcus pneumoniae was the most common infectious agent, seen in 12 patients, followed by Escherichia coli in six and negative cultures in four. Peritoneal signs of irritation were present in all patients, including in 16 who were receiving corticosteroid therapy.

In a retrospective study, eight episodes of peritonitis in seven patients over a five-year period were reported in 268 patients with nephrotic syndrome that was initially diagnosed as steroid sensitive [8]. In three cases, the causative microorganism was identified as S. pneumoniae, Streptococcus hemolyticus, and alpha-hemolytic Streptococcus.

Sepsis, meningitis, and cellulitis are other serious infections that can occur in children with nephrotic syndrome [9,10]. Although not as serious, urinary tract infections are common [6,11].

Prior to 1940, the mortality rate in children with nephrotic syndrome was 40 percent, primarily due to infection [12]. Although the mortality rate has been significantly reduced with the introduction of corticosteroid treatment and antibiotics [13,14], infection still remains a cause of death in children with nephrotic syndrome. This was illustrated in an International Study of Kidney Disease in Children report of 10 deaths in a group of 389 children with minimal change disease who were seen between 1967 and 1976 and were followed for 5 to 15 years [15]. Six of the deaths were due to infection, five were from sepsis (peritonitis as the primary site of infection in two), and one was due to peritonitis with pancreatitis. S. pneumoniae was isolated in two cases and E. coli in two other cases.

Because children with nephrotic syndrome are at increased risk for serious complications and, potentially, death from pneumococcal infection, they should receive the 23-valent polysaccharide (PPSV23) pneumococcal vaccine if not previously immunized. Pneumococcal vaccine is effective even in children receiving high doses of steroids and is not associated with an increased risk of relapse [16,17]. (See "Pneumococcal vaccination in children", section on 'Immunization of high-risk children and adolescents'.)

Viral infections — Viral infections, particularly varicella, may be observed in children with nephrotic syndrome, especially in those receiving immunosuppressive therapy. Varicella can cause significant morbidity and mortality in such patients [18-20]. Treatment, including vaccination, is discussed in greater detail separately. (See "Treatment of varicella (chickenpox) infection", section on 'Immunocompromised hosts'.)

Idiopathic nephrotic syndrome is not clear risk factor for severe coronavirus disease 2019 (COVID-19) [21]. Although relapse of nephrotic syndrome may occur as a complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, it can be effectively managed. (See "Treatment of idiopathic nephrotic syndrome in children", section on 'Initial or infrequent relapse'.)

Although live attenuated viral vaccines have been discouraged for use in children receiving immunosuppressive therapy, a prospective study reported that administration of live attenuated vaccines was immunogenic and safe in children with nephrotic syndrome receiving immunosuppressive therapy [22]. However, the children in this study, who were in remission, had reasonable cellular and humoral immunologic function as inclusion criteria for this study included CD4+ cell count >500/mm3, normal lymphocyte blast transformation by phytohemagglutinin, and serum IgG levels >300 mg/dL. Additional studies are needed to confirm the safety and response rate and identify factors that may impact immunogenicity prior to routine administration of life attenuated viral vaccines in children with nephrotic syndrome who are receiving immunosuppressive therapy.

THROMBOEMBOLISM — 

Several factors contribute to an increased risk of thromboembolic complications in children with nephrotic syndrome. Nephrotic syndrome is associated with a hypercoagulable state due to thrombocytosis and hemostatic abnormalities including decreased levels of antithrombin III, free protein S, and plasminogen (due to urinary losses); increased levels of procoagulant proteins (fibrinogen and factors V and VIII); and increased platelet activation. (See "Hypercoagulability in nephrotic syndrome", section on 'Pathogenesis'.)

Additional factors that may contribute to the risk are:

Hypovolemia with hemoconcentration

Immobility, especially in patients with anasarca

Infection [23]

Presence of a central venous catheter

Underlying genetic thrombophilic tendency [24]

In a meta-analysis of 22 studies, the overall incidence of a symptomatic thromboembolic event (TEE) in children with nephrotic syndrome was 3.6 percent, with the highest rate among infants with congenital nephrotic syndrome (9 percent) and steroid-resistant nephrotic syndrome (6.3 percent) compared with steroid-sensitive nephrotic syndrome (1.5 percent) [25]. TEEs were categorized as deep vein thrombosis (49 percent), central nervous system (14 percent), pulmonary embolism (12 percent), and renal vein thrombosis (11 percent). In one of the included studies, nearly one-half of the TEEs were associated with a central venous catheter and multivariate analysis demonstrated that the risk of TEE increased with increasing urinary protein excretion [26]. The risk has a bimodal age distribution, with a peak in infancy (due to congenital nephrotic syndrome) and adolescence [27].

However, the true incidence of TEE may be higher as many TEEs are asymptomatic. This was illustrated in a case series of 16 children with steroid-dependent minimal change disease [28]. Evaluation by ventilation-perfusion scans showed defects consistent with pulmonary embolism in 7 patients, residual changes in 10, and normal findings in only 9. In another study using dual-energy computed tomography pulmonary angiography, 28 percent of children with nephrotic syndrome without respiratory symptoms had subclinical pulmonary embolism [29].

Both arterial and venous thromboses have been reported in children with nephrotic syndrome, although a venous thrombosis complication accounted for most of the cases [26]. The most common sites include the cerebral vein, pulmonary artery, renal vein, deep leg veins, inferior vena cava, and femoral/iliac artery [30-33]. Other reported sites include the cerebral and meningeal arteries and mesenteric and hepatic veins [30,34,35].

Thromboembolic complications in children with nephrotic syndrome may be associated with significant morbidity, including cerebral venous thrombosis, pulmonary embolism, and renal vein thrombosis.

Pulmonary embolism – As mentioned above, many pulmonary emboli are silent in children with nephrotic syndrome [28]. However, there are several case reports of significant morbidity from pulmonary embolism [36-38]. Pulmonary embolism should be suspected in patients with pulmonary or cardiovascular symptoms and can be confirmed by angiography or radioisotope scanning [39].

Renal vein thrombosis – Infants with congenital nephrotic syndrome are at increased risk for renal vein thrombosis. Otherwise, renal vein thrombosis is rare in children with nephrotic syndrome, especially compared with adults. However, some children develop acute complete venous occlusion, which is characterized clinically by the sudden onset of macroscopic hematuria, flank pain and/or tenderness, and, in children with bilateral disease, acute kidney injury (AKI). In such cases, Doppler ultrasonography shows an increase in kidney size and the absence of blood flow in the renal vein. (See "Hypercoagulability in nephrotic syndrome", section on 'Pathogenesis'.)

Prophylactic anticoagulation is not recommended unless the patient has had a TEE or has a high risk of thrombosis with albumin concentration less than 2 g/dL (20 g/L), fibrinogen level more than 6 g/L, or antithrombin III level less than 70 percent of normal. (See "Symptomatic management of nephrotic syndrome in children", section on 'Hypercoagulability'.)

KIDNEY FUNCTION IMPAIRMENT — 

At presentation, children with nephrotic syndrome can have reduced glomerular filtration rate (GFR) because of one or more of the following mechanisms [40]:

Hypovolemia – Children with nephrotic syndrome, especially those with minimal change disease, can have a transient decrease in GFR due to hypovolemia that returns to normal after repletion of their vascular volume [41-43].

Acute kidney injury (AKI) in children, although uncommon, may occur as a complication of infection, acute tubular necrosis (secondary to significant hypovolemia), allergic interstitial nephritis (due to antibiotics or nonsteroidal antiinflammatory drugs), or drug toxicity such as calcineurin inhibitors (cyclosporine or tacrolimus, which are often used in children with steroid-dependent nephrotic syndrome) or angiotensin-converting enzyme inhibitors [40,42,44,45]. AKI occurs more frequently in patients who are hospitalized. In a report from the Midwest Pediatric Nephrology Consortium, almost 60 percent of children hospitalized developed AKI [44]. Associated factors included steroid-resistant nephrotic syndrome, infection, and exposure to nephrotoxic medication.

Underlying glomerular pathology – In children with nephrotic syndrome, primary kidney disease (eg, primary membranoproliferative glomerulonephritis [41]) or secondary kidney disease (eg, postinfectious glomerulonephritis or lupus nephritis) can present with kidney function impairment due to glomerular injury. (See "Poststreptococcal glomerulonephritis" and "Lupus nephritis: Diagnosis and classification" and "Focal segmental glomerulosclerosis: Treatment and prognosis", section on 'Prognosis'.)

Minimal change disease, which is the most common form of nephrotic syndrome in children, particularly in those younger than age six years, may present with mild elevations in serum creatinine, but substantial declines in GFR are uncommon [40]. In one study, a decrease in GFR appeared to correlate with an increased degree of fusion of the foot processes [46]. (See "Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children" and "Acute kidney injury (AKI) in minimal change disease and other primary forms of nephrotic syndrome".)

Progression to chronic or end-stage kidney failure can occur in some patients, especially those with steroid-resistant nephrotic syndrome. (See "Treatment of idiopathic nephrotic syndrome in children", section on 'Outcome based on response'.)

ANASARCA — 

Anasarca (generalized and massive edema) can be associated with the following complications:

Inability to walk because of severe scrotal or vulvar edema

Respiratory distress from large pleural effusions, and/or massive ascites, which can impair diaphragmatic movement

Tissue breakdown and cellulitis

Management of anasarca is discussed in detail elsewhere. (See "Symptomatic management of nephrotic syndrome in children", section on 'Edema'.)

HYPOVOLEMIA — 

Despite the marked increase in extracellular fluid volume, some children with nephrotic syndrome, primarily those with minimal change disease, present with or develop signs of a decrease in effective circulating volume such as tachycardia, peripheral vasoconstriction, oliguria, decreased glomerular filtration rate (GFR), and elevation of plasma renin aldosterone [43]. Hypovolemia typically occurs early at onset of nephrosis or during a relapse. In such children, a further insult such as diuretic therapy, sepsis, or diarrhea can lead to hypotension and, rarely, shock [47].

GROWTH — 

Growth can be adversely affected in patients with persistent nephrotic syndrome or as a complication of long-term steroid therapy in patients with steroid-dependent nephrotic syndrome. (See "Treatment of idiopathic nephrotic syndrome in children", section on 'Alternative treatments for patients with steroid toxicity' and "Causes of short stature", section on 'Glucocorticoid therapy'.)

OTHER POTENTIAL COMPLICATIONS — 

Other potential complications that may occur in children with nephrotic syndrome include:

Dyslipidemia – Hyperlipidemia in nephrotic syndrome is common and is characterized by elevated total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels with normal or low high-density lipoprotein cholesterol levels. Dyslipidemia contributes to an increased risk of cardiovascular and thrombotic complications [48,49]. This is discussed in detail elsewhere. (See "Lipid abnormalities in nephrotic syndrome", section on 'Common lipid abnormalities' and "Lipid abnormalities in nephrotic syndrome", section on 'Clinical implications'.)

Anemia – Patients with persistent nephrotic syndrome may develop anemia due to urinary losses of iron, transferrin, erythropoietin, transcobalamin, and/or metals such as copper [50].

Abnormal endocrine tests and possible function – Patients with nephrotic syndrome may have low total thyroxine (T4) and triiodothyronine (T3) levels but normal serum free T4 and T3 and thyrotropin (thyroid-stimulating hormone) concentrations and, as a result, are usually clinically euthyroid. In addition, serum calcidiol (25-hydroxyvitamin D) and calcitriol concentrations may be reduced [51], but the physiologic serum free calcitriol concentration is normal [52]. (See "Endocrine dysfunction in the nephrotic syndrome", section on 'Thyroid function' and "Endocrine dysfunction in the nephrotic syndrome", section on 'Vitamin D and calcium metabolism'.)

SOCIETY GUIDELINE LINKS — 

Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Nephrotic syndrome in children".)

SUMMARY — 

Complications result from abnormalities directly related to the nephrotic syndrome. They include the following:

Infection – Children with nephrotic syndrome have increased susceptibility to encapsulated bacterial infection, particularly peritonitis because of defects in humoral immunity. Although antibiotics have reduced the mortality rate of nephrotic syndrome due to infection, infection still remains a cause of death in children with nephrotic syndrome. (See 'Infection' above.)

Anasarca – Anasarca (generalized and massive edema) can cause respiratory distress (eg, large pleural effusions and/or massive ascites) and skin breakdown with an increased risk of cellulitis and also increases the risk of bacterial peritonitis. (See 'Anasarca' above and 'Bacterial infection' above.)

Thrombosis – Children with nephrotic syndrome are at increased risk for thrombosis due primarily to hypercoagulability from thrombocytosis and hemostatic abnormalities. Arterial and venous thromboses occur and involve a variety of different sites. (See 'Thromboembolism' above.)

Kidney function impairment – Children with nephrotic syndrome can have transient impaired kidney function at presentation because of hypovolemia, or persistent kidney function impairment because of glomerular injury from the underlying disease process. (See 'Kidney function impairment' above.)

Hypovolemia – Significant hypovolemia in children with nephrotic syndrome can be associated with hypotension, abdominal pain, and cold poorly perfused extremities. In rare and severe cases, shock can occur. (See 'Hypovolemia' above.)

Growth – Poor growth can be seen in patients with persistent nephrotic syndrome or in patients with steroid-dependent nephrotic syndrome who are treated with long-term steroid therapy. (See 'Growth' above.)

  1. Giangiacomo J, Cleary TG, Cole BR, et al. Serum immunoglobulins in the nephrotic syndrome. A possible cause of minimal-change nephrotic syndrome. N Engl J Med 1975; 293:8.
  2. Spika JS, Halsey NA, Fish AJ, et al. Serum antibody response to pneumococcal vaccine in children with nephrotic syndrome. Pediatrics 1982; 69:219.
  3. McLean RH, Forsgren A, Björkstén B, et al. Decreased serum factor B concentration associated with decreased opsonization of Escherichia coli in the idiopathic nephrotic syndrome. Pediatr Res 1977; 11:910.
  4. Anderson DC, York TL, Rose G, Smith CW. Assessment of serum factor B, serum opsonins, granulocyte chemotaxis, and infection in nephrotic syndrome of children. J Infect Dis 1979; 140:1.
  5. Ballow M, Kennedy TL 3rd, Gaudio KM, et al. Serum hemolytic factor D values in children with steroid-responsive idiopathic nephrotic syndrome. J Pediatr 1982; 100:192.
  6. Alwadhi RK, Mathew JL, Rath B. Clinical profile of children with nephrotic syndrome not on glucorticoid therapy, but presenting with infection. J Paediatr Child Health 2004; 40:28.
  7. Krensky AM, Ingelfinger JR, Grupe WE. Peritonitis in childhood nephrotic syndrome: 1970-1980. Am J Dis Child 1982; 136:732.
  8. Uncu N, Bülbül M, Yildiz N, et al. Primary peritonitis in children with nephrotic syndrome: results of a 5-year multicenter study. Eur J Pediatr 2010; 169:73.
  9. Wilfert CM, Katz SL. Etiology of bacterial sepsis in nephrotic children 1963-1967. Pediatrics 1968; 42:840.
  10. Sleiman JN, D'Angelo A, Hammerschlag MR. Spontaneous Escherichia coli cellulitis in a child with nephrotic syndrome. Pediatr Infect Dis J 2007; 26:266.
  11. Gulati S, Kher V, Arora P, et al. Urinary tract infection in nephrotic syndrome. Pediatr Infect Dis J 1996; 15:237.
  12. Barness LA, Moll GH, Janeway CA. Nephrotic Syndrome. I. Natural History of the Disease. Pediatrics 1950; 5:486.
  13. LAWSON D, MONCRIEFF A, PAYNE WW. Forty years of nephrosis in childhood. Arch Dis Child 1960; 35:115.
  14. ARNEIL GC. 164 children with nephrosis. Lancet 1961; 2:1103.
  15. Minimal change nephrotic syndrome in children: deaths during the first 5 to 15 years' observation. Report of the International Study of Kidney Disease in Children. Pediatrics 1984; 73:497.
  16. Ulinski T, Leroy S, Dubrel M, et al. High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone. Pediatr Nephrol 2008; 23:1107.
  17. Goonewardene ST, Tang C, Tan LT, et al. Safety and Efficacy of Pneumococcal Vaccination in Pediatric Nephrotic Syndrome. Front Pediatr 2019; 7:339.
  18. Close GC, Houston IB. Fatal haemorrhagic chickenpox in a child on long-term steroids. Lancet 1981; 2:480.
  19. Scheinman JI, Stamler FW. Cyclophosphamide and fatal varicella. J Pediatr 1969; 74:117.
  20. Resnick J, Schanberger JE. Varicella reactivation in nephrotic syndrome treated with cyclophosphamide and adrenal corticosteroids. J Pediatr 1973; 83:451.
  21. Morello W, Vianello FA, Proverbio E, et al. COVID-19 and idiopathic nephrotic syndrome in children: systematic review of the literature and recommendations from a highly affected area. Pediatr Nephrol 2022; 37:757.
  22. Kamei K, Miyairi I, Ishikura K, et al. Prospective Study of Live Attenuated Vaccines for Patients with Nephrotic Syndrome Receiving Immunosuppressive Agents. J Pediatr 2018; 196:217.
  23. Carpenter SL, Goldman J, Sherman AK, et al. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatr Nephrol 2019; 34:261.
  24. Ismail G, Obrișcă B, Jurubiță R, et al. Inherited Risk Factors of Thromboembolic Events in Patients with Primary Nephrotic Syndrome. Medicina (Kaunas) 2020; 56.
  25. Dadgar K, Xue Y, Chung J, et al. Childhood nephrotic syndrome and the clinical profile of thromboembolism: a systematic review and meta-analysis. Pediatr Res 2023; 93:1463.
  26. Kerlin BA, Blatt NB, Fuh B, et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr 2009; 155:105.
  27. Kerlin BA, Haworth K, Smoyer WE. Venous thromboembolism in pediatric nephrotic syndrome. Pediatr Nephrol 2014; 29:989.
  28. Hoyer PF, Gonda S, Barthels M, et al. Thromboembolic complications in children with nephrotic syndrome. Risk and incidence. Acta Paediatr Scand 1986; 75:804.
  29. Zhang LJ, Zhang Z, Li SJ, et al. Pulmonary embolism and renal vein thrombosis in patients with nephrotic syndrome: prospective evaluation of prevalence and risk factors with CT. Radiology 2014; 273:897.
  30. Cameron JS. Coagulation and thromboembolic complications in the nephrotic syndrome. Adv Nephrol Necker Hosp 1984; 13:75.
  31. Sullivan MJ 3rd, Hough DR, Agodoa LC. Peripheral arterial thrombosis due to the nephrotic syndrome: the clinical spectrum. South Med J 1983; 76:1011.
  32. Suri D, Ahluwalia J, Saxena AK, et al. Thromboembolic complications in childhood nephrotic syndrome: a clinical profile. Clin Exp Nephrol 2014; 18:803.
  33. Egli F, Elmiger P, Stalder G. [Thrombosis as a complication of nephrotic syndrome]. Helv Paediatr Acta 1973; 30:Suppl:20.
  34. Appenzeller S, Zeller CB, Annichino-Bizzachi JM, et al. Cerebral venous thrombosis: influence of risk factors and imaging findings on prognosis. Clin Neurol Neurosurg 2005; 107:371.
  35. Igarashi M, Roy S 3rd, Stapleton FB. Cerebrovascular complications in children with nephrotic syndrome. Pediatr Neurol 1988; 4:362.
  36. Deshpande PV, Griffiths M. Pulmonary thrombosis in steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2005; 20:665.
  37. Apostol EL, Kher KK. Cavitating pulmonary infarction in nephrotic syndrome. Pediatr Nephrol 1994; 8:347.
  38. Jones CL, Hébert D. Pulmonary thrombo-embolism in the nephrotic syndrome. Pediatr Nephrol 1991; 5:56.
  39. Rai Mittal B, Singh S, Bhattacharya A, et al. Lung scintigraphy in the diagnosis and follow-up of pulmonary thromboembolism in children with nephrotic syndrome. Clin Imaging 2005; 29:313.
  40. Meyrier A, Niaudet P. Acute kidney injury complicating nephrotic syndrome of minimal change disease. Kidney Int 2018; 94:861.
  41. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978; 13:159.
  42. Agarwal N, Phadke KD, Garg I, Alexander P. Acute renal failure in children with idiopathic nephrotic syndrome. Pediatr Nephrol 2003; 18:1289.
  43. Vande Walle JG, Donckerwolcke RA, van Isselt JW, et al. Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms. Lancet 1995; 346:148.
  44. Rheault MN, Zhang L, Selewski DT, et al. AKI in Children Hospitalized with Nephrotic Syndrome. Clin J Am Soc Nephrol 2015; 10:2110.
  45. Kim MY, Cho MH, Kim JH, et al. Acute kidney injury in childhood-onset nephrotic syndrome: Incidence and risk factors in hospitalized patients. Kidney Res Clin Pract 2018; 37:347.
  46. Bohman SO, Jaremko G, Bohlin AB, Berg U. Foot process fusion and glomerular filtration rate in minimal change nephrotic syndrome. Kidney Int 1984; 25:696.
  47. Yamauchi H, Hopper J Jr. Hypovolemic shock and hypotension as a complication in the nephrotic syndrome. Report of ten cases. Ann Intern Med 1964; 60:242.
  48. Hari P, Khandelwal P, Smoyer WE. Dyslipidemia and cardiovascular health in childhood nephrotic syndrome. Pediatr Nephrol 2020; 35:1601.
  49. Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 2018; 14:57.
  50. Iorember F, Aviles D. Anemia in nephrotic syndrome: approach to evaluation and treatment. Pediatr Nephrol 2017; 32:1323.
  51. Selewski DT, Chen A, Shatat IF, et al. Vitamin D in incident nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol 2016; 31:465.
  52. Banerjee S, Basu S, Akhtar S, et al. Free vitamin D levels in steroid-sensitive nephrotic syndrome and healthy controls. Pediatr Nephrol 2020; 35:447.
Topic 6102 Version 27.0

References